Lupin gets USFDA nod for generic version of Edecrin tablets to treat Edema in US
Lupin has received US Food and Drug Administration (USFDA) approval for Ethacrynic Acid tablets, a generic version of Bausch Health's Edecrin tablets, in 25 mg strength.
New Delhi: Drug maker Lupin on Monday said it has received approval from the US health regulator to market Ethacrynic Acid tablets, used to treat edema in various conditions, in the American market.
The company has received approval from the US Food and Drug Administration (USFDA) to market its product, a generic version of Bausch Health's Edecrin tablets, in 25 mg strength, Lupin said in a statement.
As per IQVIA MAT June 2019 data, Ethacrynic Acid tablets had annual sales of around USD 24 million (about Rs 170 crore) in the US.
Based in Mumbai, the company's key focus areas include pediatrics, cardiovascular, anti-infectives, diabetology, asthma, and anti-tuberculosis.
Read Also: Lupin, Boehringer Ingelheim sign USD 700 million deal for novel oncology drug
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd